Vaccinex. has been granted a patent for compositions and methods targeting semaphorin-4D (SEMA4D) to treat various diseases, including autoimmune and neurodegenerative disorders. The patent includes specific antibody compositions with defined variable regions for effective binding to SEMA4D. GlobalData’s report on Vaccinex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vaccinex, Personalized cancer vaccines was a key innovation area identified from patents. Vaccinex's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody composition targeting semaphorin-4d for disease treatment
The patent US12006365B2 describes a novel composition that includes an antibody or an antigen-binding fragment specifically targeting semaphorin-4D (SEMA4D). The composition is characterized by a heavy chain variable region (VH) and a light chain variable region (VL), with specific amino acid sequences outlined in the claims. The VH and VL are designed to exhibit a high degree of sequence identity to designated sequences, ensuring specificity and efficacy in binding to SEMA4D. Additionally, the claims encompass various configurations of the antibody, including the incorporation of human or non-human framework regions and constant regions, which can enhance the therapeutic potential of the antibody.
The patent also outlines methods for utilizing this composition in clinical applications, particularly for neutralizing SEMA4D in human subjects. These methods include treating various conditions such as cancer, autoimmune diseases, and inflammatory disorders. The claims specify that the composition can be used alone or in combination with other therapies, such as anti-cancer treatments or immunosuppressive agents, to improve patient outcomes. Furthermore, the composition is versatile, allowing for different forms such as Fab fragments and multispecific antibodies, which may enhance its therapeutic effectiveness in targeting SEMA4D and its associated pathways.
To know more about GlobalData’s detailed insights on Vaccinex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
